Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE)

202234 citationsJournal Articlegold Open Access

Authors

Maggie Czarnogorski · Zero to Three

Cindy Garris · Zero to Three

Marybeth Dalessandro · ViiV Healthcare (Spain)

Ronald D’Amico

Toyin Nwafor

Will Williams · GlaxoSmithKline (United States)

Deanna Merrill

Yuanyuan Wang · GlaxoSmithKline (United States)

Abstract

In CUSTOMIZE, cabotegravir + rilpivirine LA was successfully implemented across a range of US healthcare settings. Barriers were mitigated with minor process adjustments.

Topics & Keywords

Pharmaceutical studies and practices Pharmaceutical Practices and Patient Outcomes Pediatric Pain Management Techniques

Publication Details

Published in: Journal of the International AIDS Society

Volume 25, Issue 9, pp. e26003-e26003

DOI: 10.1002/jia2.26003

Field-Weighted Citation Impact: 11.04

Command Palette

Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE)

Authors

Abstract

Topics & Keywords

Publication Details